Executive Summary
A recent Endpoints Signal Pulse Report reveals that half of biopharma professionals now consider themselves heavy AI users, signaling a major shift from experimental adoption to integral application across research and development.
While current AI impact is mixed—only 15% of respondents say it is transformative today—heavy AI users report real workflow changes, from predictive modeling in hit-to-lead campaigns to AI-generated regulatory documents. Looking ahead, three-quarters of respondents expect AI to radically transform drug discovery and development by 2030, highlighting the growing influence of AI across the industry.
Current Impact of AI in Biopharma
Despite widespread adoption, AI’s role today remains patchy:
- Over 50% of respondents rated AI impact as modest or inconsequential.
- Heavy users report tangible benefits in:
- Drug molecule optimization and hit-to-lead workflows
- Biologics design and biomarker identification
- Early-stage cancer detection (e.g., chest X-rays)
- Optimizing preclinical and clinical trial protocols
- Reducing reliance on animal testing through in silico simulations
“AI is driving modest workflow improvements today, but its real promise lies ahead,” noted Tom Randall, VP at Endpoints News.
The Five-Year Transformation
Optimism is high for AI’s near-term impact:
- 75% of respondents expect drug R&D to be fundamentally transformed by 2030.
- 12% believe transformative change could happen within just three years.
- Industry actions underpinning this shift include:
- Eli Lilly building an AI supercomputer with over 1,000 Nvidia GPUs
- OpenFold3 initiative, pooling protein data across labs including Johnson & Johnson, Bristol Myers Squibb, Takeda, AbbVie, and others
- Multi-billion-dollar AI licensing and funding deals across discovery platforms
Heavy AI users are particularly bullish, with 90% expecting drug discovery to look entirely different within five years.
Challenges to Adoption
AI adoption is not without hurdles:
- Translating models into real-world biology (43%)
- Access to high-quality biological data (31%)
- Workflow integration (13%)
- Surprisingly, compute costs and leadership buy-in were less significant obstacles
These results indicate that the “last mile” of AI deployment lies in cleaning, labeling, and integrating complex biological datasets into existing workflows.
Who Stands to Win the AI Race?
The AI revolution in biopharma is increasingly a competition between:
- Big pharma incumbents, leveraging extensive clinical datasets, trial networks, and capital
- Tech newcomers, who bring advanced software, infrastructure, and novel AI tooling
Survey respondents note that tech entrants may not invent blockbuster drugs directly but are likely to dominate software, model development, and infrastructure layers, becoming indispensable to the R&D ecosystem.
Key Takeaways
- Experience matters: Heavy AI users report higher current impact, greater optimism, and less concern about workflow integration.
- Executives and scientists are more bullish than finance professionals.
- AI is already contributing to drug molecule optimization, biomarker discovery, and clinical trial planning.
- Data access and biological validation remain the main constraints to broader AI adoption.
David Reese, CTO of Amgen, describes the opportunity as a “staggering resource sitting in front of us,” likening untapped biopharma data to undiscovered oil in the mid-19th century.
Outlook
As AI becomes an integral part of R&D, companies leveraging it effectively in workflows, data management, and discovery pipelines will gain a competitive edge. By 2030, drug discovery and development are expected to be unrecognizable from today’s processes, driven by AI-enabled insights, automation, and predictive capabilities.
By